Study of om336 for kidney transplant candidates with high antibodies
Part of Immune system & allergy, Kidney & urinary clinical trials.
This trial tests an experimental drug called om336 to lower antibodies that make it hard to receive a kidney transplant. It aims to help people who have been waiting a long time for a kidney due to high antibody levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You are on the waiting list for a deceased donor kidney and have high antibody levels (more than 85% panel reactive antibodies) for at least 24 months, or you are a living donor candidate with antibodies against the donor.
- A blood test at screening must show that diluting your serum reduces the antibody level significantly.
- You are not pregnant or breastfeeding, and if you can have children, you agree to use effective birth control during the study.
- You are up to date on recommended vaccinations within 4 weeks before starting.
- You have not had any previous treatment with therapies targeting BCMA or CD3, and you have not had other antibody-lowering treatments in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
This trial tests a new CAR-T therapy that targets immune cells to reduce harmful antibodies in highly sensitized kidney transplant candidates. The goal is to help your body accept a kidney from a donor that would otherwise be rejected.
This trial tests a new medicine called imlifidase that quickly removes harmful antibodies from the blood. It is given to children before a kidney transplant to make the donated kidney more likely to be accepted, especially when standard desensitisation methods have failed.
This study tests whether a medication called belimumab can help people who are highly sensitized (their immune system has many antibodies against donor organs) become eligible for kidney transplant by improving how doctors understand their antibody patterns. The goal is to help these patients access transplants more easily.
This early-phase trial tests a new therapy that uses your own immune cells to reduce your body's attack on a new kidney. It aims to help people who are highly sensitized (hard to match) get a transplant successfully.
This study tests a new combination of drugs (an antibody called CD38 mAb plus azathioprine) to treat a type of chronic rejection that can happen months or years after a kidney transplant. The goal is to see if it can help stabilize or improve kidney function and prevent further damage.
Hear when a new Highly Sensitized Patients Awaiting Kidney Transplant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.